2007
Transketolase (TKT) gene variability as a potencial susceptibility factor for diabetic nephropathy
PÁCAL, Lukáš, Andrea STEJSKALOVÁ, Veronika TANHÄUSEROVÁ a Kateřina KAŇKOVÁZákladní údaje
Originální název
Transketolase (TKT) gene variability as a potencial susceptibility factor for diabetic nephropathy
Název česky
Transketolase (TKT) gene variability as a potencial susceptibility factor for diabetic nephropathy
Autoři
PÁCAL, Lukáš (203 Česká republika, garant), Andrea STEJSKALOVÁ (203 Česká republika), Veronika TANHÄUSEROVÁ (203 Česká republika) a Kateřina KAŇKOVÁ (203 Česká republika)
Vydání
20th Annual Meeting Edinburgh, Scotland, May 11 - 12, 2007, 2007
Další údaje
Jazyk
angličtina
Typ výsledku
Konferenční abstrakt
Obor
30202 Endocrinology and metabolism
Stát vydavatele
Velká Británie a Severní Irsko
Utajení
není předmětem státního či obchodního tajemství
Kód RIV
RIV/00216224:14110/07:00019057
Organizační jednotka
Lékařská fakulta
Klíčová slova anglicky
transketolase; polymorphism; diabetic nephropathy
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 2. 4. 2010 15:08, prof. MUDr. Kateřina Kaňková, Ph.D.
V originále
Objective: Accumulation of proximal glycolytic intermediates - due to the allosteric inhibition of enzymes, changed NADH/NAD+ ratio and modification of the glycolytic enzyme glyceraldehyd-3-phosphate dehydrogenase provides substrates for the metabolic pathways plays contributing to the pathogenesis of diabetic complications (such as formation of Advanced Glycation End-products (AGEs), polyols, hexosamines etc.). Pentose phosphate pathway (PPP) represents potentially "protective" mechanism in hyperglycemia since shunting of cumulated glycolytic intermediates (esp. triosephosphates) into the PPP reactions supposedly "disburdens" glycolysis and quantitatively limits processing of glycolytic intermediates in the alternative metabolic pathways. We hypothesized that genetic variability in the rate-limiting enzyme of the PPP non-oxidative branch - transketolase - contributes to an interindividual variability in the onset and progression of diabetic nephropathy (DN). Subjects and Methods: Study comprised 421 subjects (204 DM non-DN and 217 DM+DN subjects) In the first phase, SNPs with MAF >10% in the Caucasian population were selected with the density 1 per haplotype block (htSNPs) in the TKT gene (MIM no. 606781, chrom. 3p14.3). In pilot experiments those with high pair-wise LD were excluded, remaining 6 SNPs (rs2279323, rs3736156, rs1051483, rs12487632, rs968702 and rs13101181) to be genotyped in the whole study sample. SNPs were detected by means of polymerase chain reaction (PCR) using fluorescent-labelled probes (TaqMan, Applied Biosystems). Haplotypes were constructed based on genotype data using Bayesian algorithm (PHASE). Differences in haplotype frequencies between the groups will be tested by permutation testing. Logistic regression (incl. input variables such as age and gender, DM duration, fasting glycemia, HbA1c, microalbuminuria, proteinuria and GFR), survival analysis (Kaplan-Meier) and Cox proportional hazard regression were used to assess the risk of disease-associated haplotypes. Conclusions: Results suggest that TKT variability might play a role in the individual susceptibility to the development of DN.
Česky
Objective: Accumulation of proximal glycolytic intermediates - due to the allosteric inhibition of enzymes, changed NADH/NAD+ ratio and modification of the glycolytic enzyme glyceraldehyd-3-phosphate dehydrogenase provides substrates for the metabolic pathways plays contributing to the pathogenesis of diabetic complications (such as formation of Advanced Glycation End-products (AGEs), polyols, hexosamines etc.). Pentose phosphate pathway (PPP) represents potentially "protective" mechanism in hyperglycemia since shunting of cumulated glycolytic intermediates (esp. triosephosphates) into the PPP reactions supposedly "disburdens" glycolysis and quantitatively limits processing of glycolytic intermediates in the alternative metabolic pathways. We hypothesized that genetic variability in the rate-limiting enzyme of the PPP non-oxidative branch - transketolase - contributes to an interindividual variability in the onset and progression of diabetic nephropathy (DN). Subjects and Methods: Study comprised 421 subjects (204 DM non-DN and 217 DM+DN subjects) In the first phase, SNPs with MAF >10% in the Caucasian population were selected with the density 1 per haplotype block (htSNPs) in the TKT gene (MIM no. 606781, chrom. 3p14.3). In pilot experiments those with high pair-wise LD were excluded, remaining 6 SNPs (rs2279323, rs3736156, rs1051483, rs12487632, rs968702 and rs13101181) to be genotyped in the whole study sample. SNPs were detected by means of polymerase chain reaction (PCR) using fluorescent-labelled probes (TaqMan, Applied Biosystems). Haplotypes were constructed based on genotype data using Bayesian algorithm (PHASE). Differences in haplotype frequencies between the groups will be tested by permutation testing. Logistic regression (incl. input variables such as age and gender, DM duration, fasting glycemia, HbA1c, microalbuminuria, proteinuria and GFR), survival analysis (Kaplan-Meier) and Cox proportional hazard regression were used to assess the risk of disease-associated haplotypes. Conclusions: Results suggest that TKT variability might play a role in the individual susceptibility to the development of DN.
Návaznosti
| NR9443, projekt VaV |
|